← Back to Search

Genetic Test

Genetic Testing for Acute Coronary Syndrome (ACCURATE Trial)

N/A

Recruiting

Led By Liam Brunham, MD PhD

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Admitted to an acute cardiac unit with either a ST elevation myocardial infarction (STEMI) or a non-ST elevation myocardial infarction (NSTEMI)

Maximum lipid level at the time of admission or during the prior 1 year of: LDL level ≥4 mmol/L (154 mg/dL) if not on a statin, LDL-C level ≥2.5 mmol/L (96 mg/dL) if on a statin prior to presentation, Non-HDL-C ≥4.6 mmol/L (177 mg/dL) if LDL-C not available

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

ACCURATE Trial Summary

This trial will test whether genetic testing for Familial Hypercholesterolemia (FH) in patients admitted to hospital with an acute coronary syndrome will increase the diagnosis of FH and improve patient care and outcomes.

Who is the study for?

This trial is for people under 60 who've been admitted to a cardiac unit with a heart attack (STEMI or NSTEMI) and have high cholesterol levels. It's not open to those already diagnosed with Familial Hypercholesterolemia or on certain lipid treatments.Check my eligibility

What is being tested?

The ACCURATE study tests if genetic testing for Familial Hypercholesterolemia in patients hospitalized for acute coronary syndrome can help diagnose this condition and influence their treatment and health outcomes.See study design

What are the potential side effects?

Since the intervention involves genetic testing, there are no direct physical side effects. However, receiving genetic information may have psychological impacts or affect insurance status.

ACCURATE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I was admitted for a heart attack.

Select...

My cholesterol levels have been high in the past year.

Select...

I am younger than 60 years old.

ACCURATE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of patients with a new diagnosis of FH

Secondary outcome measures

Lowest LDL-cholesterol (LDL-C) level achieved in the first year after ACS

Proportion of patients in whom lipid-lowering medication intensified, as defined by an increase the dose of statin, or the addition of a non-statin lipid-lowering medication, in the first year after ACS

Proportion of patients who achieve guideline recommended lipid targets in the first year after ACS

Other outcome measures

Rate of recurrent cardiovascular event in the first year after ACS

ACCURATE Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Active-testingExperimental Treatment1 Intervention

Those admitted between 6-18 months of the study meeting the inclusion criteria. Saliva samples will be collected for DNA testing.

Group II: ObservationActive Control1 Intervention

Those admitted in the first 6 months of the study that meet the inclusion criteria. Patients will be treated according to the normal standard of care for acute coronary syndrome.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Genome British ColumbiaIndustry Sponsor

12 Previous Clinical Trials

222,992 Total Patients Enrolled

Vancouver Coastal Health Research InstituteOTHER

26 Previous Clinical Trials

4,940 Total Patients Enrolled

University of British ColumbiaLead Sponsor

1,418 Previous Clinical Trials

2,466,868 Total Patients Enrolled

4 Trials studying Hypercholesterolemia

275 Patients Enrolled for Hypercholesterolemia

Media Library

Research-based genetic test for Familial Hypercholesterolemia (Genetic Test) Clinical Trial Eligibility Overview. Trial Name: NCT05218005 — N/A

Hypercholesterolemia Research Study Groups: Active-testing, Observation

Hypercholesterolemia Clinical Trial 2023: Research-based genetic test for Familial Hypercholesterolemia Highlights & Side Effects. Trial Name: NCT05218005 — N/A

Research-based genetic test for Familial Hypercholesterolemia (Genetic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05218005 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the current research trial open to individuals aged 40 and over?

"To meet the requirements for this study, prospective patients must be 18 years or older and under 60."

Answered by AI

Is participation in the experiment open to me?

"This clinical trial is searching for 250 individuals between 18 and 60 years of age who have been diagnosed with acute coronary syndrome. Additionally, the participants must meet other conditions such as having a LDL level greater than 4 mmol/L (154 mg/dL) if not taking statins or 2.5 mmol/L (96 mg/dL) on a current statin regimen, in addition to Non-HDL-C ≥4.6 mmol/L (177 mg/dL)."

Answered by AI

How many participants are enrolled in the current clinical experiment?

"Affirmative, the records on clinicaltrials.gov prove that this investigation is still open to new participants. It was posted initially on January 1st 2022 and updated lastly at the end of January 2021. The research aims to recruit a total of 250 individuals from two distinct sites."

Answered by AI

Does this investigation have any open enrollment spots?

"Affirmative. According to clinicaltrials.gov, this medical trial is actively searching for participants and was first posted on January 1st 2022 with a subsequent edit made at the end of the month. From two different sites combined, 250 individuals must be enrolled in order to complete the study's objectives."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia

Liam Brunham 2022. "Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05218005.

All > Heart Attack > Cholesterol